All patients must have had an axillary ultrasound with fine needle aspiration (FNA) or core needle biopsy of axillary lymph nodes documenting axillary metastasis at the time of diagnosis, prior to or at most 14 days after starting neoadjuvant chemotherapy\r\n* Note: Biopsy of intramammary nodes does not fulfill eligibility criteria
Patients with histologically positive axillary nodes post neoadjuvant therapy
Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes
Diagnosed with pathologically (histologically) proven invasive mammary carcinoma (ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy with any type of axillary surgery or axillary sampling
INCLUSION - ENROLLMENT: cT1-2N0 on clinical staging (verified to have no suspicious axillary or internal mammary nodes on magnetic resonance imaging [MRI] or ultrasound)
Metastatic breast cancer (local spread to axillary or internal mammary lymph nodes is permitted)
(For Cohort B only): Presence of metastatic disease or prior radiation therapy of the primary breast carcinoma or axillary lymph nodes
Either clinically positive (N1 only) or clinically negative axillary nodes (N0)
Patients have had prior radiotherapy for primary breast carcinoma or axillary lymph nodes
More than 3 histologically positive axillary lymph nodes or axillary lymph nodes with microscopic or macroscopic extracapsular extension
Positive non-axillary sentinel nodes or evidence of suspicious supraclavicular, infraclavicular, or internal mammary nodes by imaging or physical exam, unless biopsied and found to be negative for tumor
Patients who had prior radiation therapy of the primary breast carcinoma or axillary lymph nodes
Prior radiation therapy of the primary breast carcinoma or axillary lymph nodes
N-1, N-2, or N-3 pathologic axillary nodes
Any non-axillary sentinel node(s) positive; (note that intramammary nodes are staged as axillary nodes)
Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histological confirmation that these nodes are negative for tumor
More than 3 histologically positive axillary nodes
Axillary nodes with definite evidence of microscopic or macroscopic extracapsular extension
Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes at time of enrollment unless there is histologic confirmation that these nodes are negative for tumor
Greater than 9 positive axillary nodes/sentinel biopsy
Palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor
More than 3 positive axillary nodes on imaging or matted nodes on clinical exam
Clinically positive axillary lymph nodes
For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node biopsy [SNB] alone or axillary dissection [with a minimum of six axillary nodes removed], and the axillary node[s] must be pathologically negative); patients over 70 with estrogen receptor positive (ER+) tumors no greater than 2 cm do not require axillary evaluation, but MUST be clinically node negative on examination and all available imaging (clinical N0)
Prior axillary dissection.
One to 5 involved lymph nodes identified at axillary staging
More than 5 involved nodes identified at axillary staging
Participants who have undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes
American Joint Committee on Cancer (AJCC) 7th edition stage 0 or I (Tis N0 =< 2 cm or T1 N0) histologically confirmed carcinoma of the breast, treated with partial mastectomy; axillary sampling is required only for cases of invasive cancers; tumor size is determined by the pathologist; clinical size may be used if the pathologic size is indeterminate; patients with invasive cancer must have no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node
Histologically confirmed positive axillary nodes in the ipsilateral axilla; palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor
Primary tumor =< 4 cm and 0-3 positive axillary lymph nodes (T1-2, N0-1, M0)
Pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy
Participants must have histologically confirmed invasive breast cancer confined to the breast and regional lymphatics (supraclavicular, axillary, internal mammary lymph nodes)
Locally advanced or metastatic Her2/Neu positive breast cancer (defined as immunohistochemistry [IHC] 3+ or a fluorescence in situ hybridization [FISH] ratio of >= 2.0); this may be on either a primary tumor or a metastatic site, and there is no time limit from the time the specimen was obtained; locally advanced breast cancer (LABC) includes breast cancers with advanced primary tumors, i.e., large diameter (at least 5 cm) or those with skin and/or chest wall involvement, and advanced regional lymph node involvement; it also includes a rare subgroup, inflammatory breast cancer; in the 2010 American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) TNM breast cancer staging system, locally advanced breast cancer (LABC) includes patients with stage III disease; this comprises:\r\n* Advanced primary tumors (tumors > 5 cm in greatest dimension [T3]; direct extension to the chest wall and/or to the skin [T4]: ulceration, skin nodules, and/or edema (including peau d'orange) confined to the same breast, inflammatory breast cancer [IBC, T4d])\r\n* Advanced regional lymph nodes (ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted or clinically detected internal mammary lymph nodes in the absence of axillary lymph node metastases [N2], ipsilateral infraclavicular [level III axillary] lymph nodes, ipsilateral internal mammary lymph node[s] with axillary lymph nodes, or ipsilateral supraclavicular lymph nodes [N3])
Patients with 4 or more histologically positive axillary nodes if axillary dissection is performed
Patients must not have any palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes unless there is histologic confirmation that these nodes are negative for tumor
4 or more axillary lymph nodes involved with cancer
Axillary lymph nodes negative by pre-operative physical examination in all cases and pathologic examination from surgery for invasive disease
Clinically or pathologically positive axillary lymph nodes
Definitive evidence of metastatic disease with exception of axillary lymph nodes or mammary nodes
Metastatic breast cancer (local spread to axillary lymph nodes is permitted).
No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes
No evidence of disease outside the breast or chest wall, except ipsilateral axillary or internal mammary lymph nodes
Planned for bilateral axillary surgery
Status post mastectomy with surgical assessment of axillary nodes
If PMRT is recommended, the treatment fields will include the axillary, supraclavicular, and internal mammary nodes
Participants undergoing preoperative systemic therapy must have residual invasive disease in the breast or axillary lymph nodes at the time of definitive surgery
Treatment with total mastectomy and axillary dissection; or breast-sparing surgical removal of cancer with clear macroscopic margins and axillary dissection; followed by adjuvant breast radiation
Patients with persistent palpable axillary nodes after NAC, as assessed by physical exam
Prior surgical axillary procedure including SLND or axillary node excision
CHILD: If applicable, willingness of the patient to shave axillary (armpit) hair
Patient must have a negative (normal) axillary ultrasound performed at Siteman Cancer Center; lymph nodes will be evaluated based on morphologic features; axillary ultrasound (AUS) will be considered positive (abnormal) if lymph nodes are noted to be completely hypoechoic (absent hilum) or to have focal hypoechoic cortical thickening/lobulation greater than 4 mm
No abnormal axillary nodes identified on grayscale axillary ultrasound (AUS), or abnormal nodes with benign subsequent FNA biopsy
Lymph node (LN) lesion that measures at least 1 dimension as ?1.5 centimeter (cm) in the short axis;
The presence of known lung or liver metastases greater than 1.0 cm in the long axis diameter
The presence of lymphadenopathy greater than 3 cm in the short-axis diameter
T4, node positive or advanced rectal adenocarcinoma. Node positivity defined as nodes greater than 1cm in short axis with loss of uniform cortex/fatty hilum.
Patients must have measurable disease, defined as at least one lesion above and below the diaphragm or stage 4 disease that can be accurately measured in at least one dimension; lymph nodes should be considered abnormal if the long axis is > 1.5 cm, regardless of the short axis
Pancreatic target tumor diameter of ? 2.0 cm (shortest axis) to ? 6.0 cm (longest axis) and a minimum tumor volume of 14.0 cc as qualified by the central reading center
At least 1 measurable lesion according to modified RECIST Version 1.1 (non?nodal lesions must be ?1.0 cm in the long axis or ?double the slide thickness in the long axis) within 21 days prior to the first dose of study drug.
At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma (Cheson Criteria); the site of disease must be greater than 1.5 cm in the long axis regardless of short axis measurement or greater than 1.0 cm in the short axis regardless of long axis measurement, and clearly measurable in 2 perpendicular dimensions
Lymphadenopathy exceeding 6 cm in short-axis diameter
Patients with contralateral hilar involvement (greater than 1.5 cm on short axis or positive on PET scan, or biopsy-proven)
Must have at least 1 node greater than 1.5 cm in short axis diameter
Para-aortic nodal involvement above the level of the common iliac nodes or L3/L4 (if biopsy proven, PET positive or > 15mm short axis diameter on CT)
Patients with pelvic and/or retroperitoneal lymph nodes < 1.5 cm in short axis are eligible
Have measurable disease based as defined by at least one lesion that can be measured in least 2 perpendicular dimensions and measures at least 1.5 cm in its long axis
Evidence of nodal disease greater than or equal to 15 mm in short axis as these findings are concerning for metastases that would not be targeted with radium-223 alone (Arm B); however, lymph nodes with short axis measurements between 1.5-3 cm that have not enlarged more than 5mm (to account for reader variability) over the last 6 months and which are not inducing symptoms, causing obstruction, or in the opinion of the investigator pose a risk of impending obstruction of any structures, will be allowed
Para-aortic nodal involvement above the level of the common iliac nodes or L3/L4 (if biopsy proven, PET positive, or >= 15 mm short-axis diameter on computed tomography [CT])
A PET/computed tomography (CT) scan is required; patients with hilar or mediastinal lymph nodes with short axis diameter =< 1 cm and no abnormal hilar or mediastinal uptake on PET will be considered N0; patients with > 1 cm short axis diameter of hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer; solitary pulmonary lesions =< 6 mm will not be considered significant
Nonhepatic lesion c. Lymph node (LN) lesion that measures at least one dimension as greater than or equal to 1.5 cm in the short axis, except for porta hepatis LN that measures greater than or equal to 2.0 cm in the short axis d. Non-nodal lesion that measures greater than or equal to 1.0 cm in the longest diameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.
Participants must have measurable disease, including at least one of the following: an absolute B cell count > 5000/uL, OR lymphadenopathy with at least one lymph node > 2 cm in long axis, OR palpable splenomegaly, OR cytopenias (hemoglobin [Hb] < 11 g/dL or platelets < 100 K) together with bone marrow infiltration
Measurable disease (NHL: At least 1 measurable site of disease [>1.5 centimeter [cm] in the long axis regardless of short axis measurement or >1.0 cm in the short axis regardless of long axis measurement, and clearly measurable in 2 perpendicular dimensions])
Lymphadenopathy exceeding 3 cm in short-axis diameter
Malignant lymphadenopathy exceeding 3 cm in short-axis diameter.
Malignant lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter
Lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter
Patients with pelvic and/or retroperitoneal nodes < 2 cm in short axis are eligible as they are not considered to have definitive metastases
Baseline fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scans must demonstrate positive lesions compatible with computed tomography (CT) defined anatomical tumor sites\r\n* CT scan showing at least:\r\n** 2 or more clearly demarcated lesions/nodes with a long axis > 1.5 cm and short axis >= 1.0 cm OR\r\n** 1 clearly demarcated lesion/node with a long axis > 2.0 cm and short axis >= 1.0 cm
Radiographically measurable disease, defined as: 2 or more clearly demarcated lesions/nodes with a long axis >1.5 cm and short axis ?1.0cm. OR 1 clearly demarcated lesion/node with a long axis >2.0 cm and short axis ?1.0cm.
Visceral metastases (including cerebral metastases) from castration-resistant prostate cancer (CRPC) (> 2 lung and/or liver metastases [size >= 2 cm]; lymphadenopathy exceeding 6 cm in short-axis diameter or any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis), as assessed by computed tomography (CT), magnetic resonance imaging (MRI) or chest X-ray within the 8 weeks prior to registration
Definite evidence of metastatic prostate cancer, in the opinion of the treating physician; pelvic and retroperitoneal lymph nodes < 2.0 cm in short axis are allowed
CT scans showing involvement of 1 or more clearly demarcated lesions with a long axis > 1.5 cm and short axis >= 1.0 cm
At least one of the brain lesions must measure 5 mm (or more) in short axis diameter in the axial plane
Lymph node (LN) lesion that measures at least one dimension as ?1.5 cm in the short axis, except for porta hepatis LN that measures ?2.0 cm in the short axis
At least 1 lesion of greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node that is serially measurable according to irRECIST (immune-related RECIST) using computerized tomography/magnetic resonance imaging (CT/MRI)
Patients must have at least one cutaneous or subcutaneous tumor, measuring 0.5 to 5.0 cm in the longest diameter, or a palpable lymph node. At least one tumor must qualify as an index lesion that can be accurately and reproducibly measured in two dimensions for which the longest diameter is .10 mm (.15 mm in short axis diameter [SAD] for lymph nodes), and be amenable to intratumoral injection.
Measurable disease (at least 1 lesion ?10 mm longest diameter or for lymph nodes short axis ?15 mm) by CT/MRI
At least 1 lesion of greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node that is serially measurable according to irRECIST using computerized tomography/magnetic resonance imaging (CT/MRI)
Measurable disease based on RECIST 1.1 (Or based on IWG [Cheson, 2007] [i.e., measurement must be >15 mm in longest diameter or >10 mm in short axis] for rrcHL participants)
Have measurable disease based on RECIST v.1.1 and irRC for response assessment\r\n* Must have at least one lesion that is 10 mm in longest diameter for a soft tissue lesion or 15 mm in short axis for a lymph node
Have at least one radiologically measurable lesion as per RECIST v1.1 defined as a lesion that is at least 10 mm in longest diameter or lymph node that is at least 15 mm in short axis imaged by CT scan or MRI and obtained by imaging within 28 days prior to start of study treatment. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
Measurable disease according to RECIST 1.1 and irRECIST. At least one lesion of at least 1.0 cm in the long-axis diameter for a non-lymph node or at least 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 and irRECIST using either computed tomography (CT) or magnetic resonance imaging (MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least 1.5 cm
Patients must have evaluable disease as defined by RECIST 1.1 with tumor lesion > 10 mm by computed tomography (CT) scan or caliper measurement on clinical exam or lymph node >= 15 mm in short axis
Measurable disease by RECIST v1.1 criteria (tumor >= 1 cm in longest diameter on axial image on computed tomography [CT] or magnetic resonance imaging [MRI] and/or lymph node(s) >= 1.5 cm in short axis on CT or MRI) on baseline imaging
All patients must have measurable disease as defined by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST); measurable disease is defined as 10 mm in the longest diameter by computed tomography (CT) or magnetic resonance imaging (MRI) scan (or no less than double the slice thickness) for non- nodal lesions and >= 15 mm in short axis for nodal lesions, 20 mm by chest X-ray, a lymph node must be >= 15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm)
No radiographic evidence of lymph node positive disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (>= 15 mm short axis diameter); lymph node positive disease is defined as clinical lymphadenopathy on staging computed tomography (CT) or magnetic resonance imaging (MRI) greater than 1.4 cm in the short axis; if a lymph node is greater than 1.4 cm, it has to be biopsy proven negative for the patient to be eligible
Must have measurable disease (?1 lesion that is >15 mm in the longest diameter or by >10 mm in the short axis)
At least 1 lesion of ?1.0 centimeter (cm) in the longest diameter for a non-lymph node or ?1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI).
Participants must have measurable disease as defined by response evaluation criteria in solid tumors (RECIST) 1.1 (soft tissue lesion of greater than or equal to (>=) 10 millimeter (mm) in the long axis or extrapelvic lymph node of >=15 mm in the short axis)
Patients must have baseline imaging within 30 days prior to the start of therapy and satisfy one of the following:\r\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\r\n* At least one non lymph node lesion of >= 1.0 cm or lymph node >= 1.5 cm in short axis by computerized tomography (CT) scan (CT scan thickness no greater than 5 mm which is serially measurable according to RECIST 1.1 using either computerized tomography (CT) or magnetic resonance imaging (MRI)\r\n* Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST 1.1 to be deemed a target lesion\r\n* Non-measurable disease by RECIST 1.1 criteria (includes bone only disease and lesions < 10 mm or lymph nodes < 15 mm in short axis) with rising serum CA15-3 or CA 27.29 or CEA documented by two consecutive measurements taken at least 14 days apart with the most recent measurement being within 42 days prior to registration. The second CA 15-3 or CA 27.29 value must have at least a 20% increase over the first and for CA 15-3 or CA27.29 be greater than or equal to 40 units/mL or for CEA be greater than or equal to 4 ng/mL
At least 1 tumor 10mm in diameter or greater OR lymph node of at least 15 mm in short axis
At least 1 lesion of ? 10 millimeters (mm) in the longest diameter for a non-lymph node or ? 15 mm in the short-axis diameter for a lymph node which is serially measurable according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 using computerized tomography (CT) or magnetic resonance imaging (MRI).
Have measurable disease at Screening by computed tomography (CT) (or magnetic resonance imaging [MRI]) as defined by at least 1 lesion of greater than or equal to 1.5 cm in the longest diameter for a non-lymph node or greater than or equal to 1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to the modified RECIST criteria
Measurable disease per RECIST version (v)1.1 criteria: at least 1 lesion of > 10 mm in long axis diameter for non-lymph nodes or > 15 mm in short axis diameter for lymph nodes that is serially measurable according to RECIST 1.1 using computerized tomography, magnetic resonance imaging, or panoramic and close-up color photography
Presence of measurable disease meeting the following criteria: at least 1 lesion of > 10 mm in long axis diameter for non-lymph nodes or > 15 mm in short axis diameter for lymph nodes that is serially measurable according to RECIST version 1.1 using computerized tomography, magnetic resonance imaging, or panoramic and close-up color photography
DLBCL participants must have the following malignancy criteria: measurable and evaluable disease per tumor response criteria and ? 1 tumor mass that is ? 15 mm (long axis of lymph node) or ? 10 mm (short axis of lymph node or extra nodal lesions) on spiral CT scan; failed 2 standard lines of therapy (at least one containing an anti-CD20 monoclonal antibody), or for whom such treatment is contraindicated.
Patients with the presence of at least one lesion with measurable disease as defined by 10 mm in longest diameter for a soft tissue lesions or 15 mm in short axis for a lymph node by RECIST 1.1
Patients with the presence of at least one lesion with measurable disease as defined by 10 mm in longest diameter for a soft tissue lesions or 15 mm in short axis for a lymph node by RECIST 1.1 and irRC criteria for response assessment
Participants must have metastatic, unresectable locally advanced, or locally recurrent HER2-positive breast cancer; for the phase II portion of the study, it is required that participants have measurable disease, as defined by RECIST 1.1, which can be accurately evaluated on computerized tomography (CT) or magnetic resonance imaging (MRI); measurable disease is defined as: at least one lesion of > 10 mm in the longest diameter for a non-lymph node or > 15 mm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1.criteria
At least one lesion of at least 1.0 cm in the long-axis diameter for a non-lymph node or at least 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) using either computerized tomography (CT) or magnetic resonance imaging (MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least 1.5 cm.
Have histologically or cytologically proven invasive breast cancer, locally recurrent or metastatic, with at least one measurable lesion according to RECIST v 1.1; measurable disease is defined as: at least one lesion of >= 10 mm in the longest diameter for a non-lymph node or >= 15 mm in the short-axis diameter for a lymph node which is serially measurable according to RECIST criteria, using computed tomography (CT) or magnetic resonance imaging (MRI)
Has measurable disease (at least one lesion, not irradiated within 12 weeks of study randomisation, with longest diameter more or equal 10mm (lymph nodes minimum more or equal 15 mm) with CT or MRI).
Measurable disease according to RECIST 1.1; at least one lesion of at least 1.0 cm in the long-axis diameter for a non-lymph node or at least 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using either computed tomography (CT) or magnetic resonance imaging (MRI); if there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least 1.5 cm
Presence of measurable disease meeting the following criteria:\r\n* At least one lesion of >= 1.0 cm in long axis diameter for non-lymph nodes or >= 1.5 cm in short axis diameter for lymph nodes that is serially measurable according to RECIST 1.1 using either computerized tomography or magnetic resonance imaging or panoramic and close-up color photography with caliper measurement; if there is only one target lesion and it is a not a lymph node, it should have a long-axis diameter of at least 1.5 cm\r\n* Lesions that have had radiotherapy must show radiographic evidence of disease progression based on RECIST 1.1 may be deemed a target lesion
Have at least one radiologically measurable lesion as per RECIST v1.1 defined as a lesion that is at least 10 mm in longest diameter or lymph node that is at least 15 mm in short axis imaged by CT scan or MRI and obtained by imaging within 28 days prior to start of study treatment. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
At least 1 measurable breast cancer lesion that is ? 10mm in one dimension (or ?15mm in shortest axis for lymph nodes) by spiral CT scan or by brain MRI
At least 1 lesion of >=10 millimeter (mm) in long axis diameter for nonlymph nodes or >=15 mm in short axis diameter for lymph nodes that is serially measurable according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) using computerized tomography (CT) or magnetic resonance imaging (MRI) or panoramic and close-up color photography.
Size: Lesion can be accurately measured in at least one dimension with a longest diameter ? 10mm, or for lymph nodes ? 15mm short axis. Lesions meeting size criteria will be considered measurable.
Patients with measurable disease per RECIST 1.1 criteria\r\n* At least one lesion of >= 1.5 cm in long-axis diameter for non lymph nodes or >= 1.5 cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST 1.1 using either computerized tomography (CT) or magnetic resonance imaging (MRI)\r\n* Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST 1.1 to be deemed a target lesion
At least one lesion of greater than or equal to 1.0 cm in long-axis diameter for non lymph nodes or greater than or equal to 1.5 cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST 1.1 using either computerized tomography or magnetic resonance imaging or panoramic and close-up color photography.
At least 1 lesion of ?10 millimeters (mm) in the longest diameter for a nonlymph node or ?15 mm in the short axis diameter for a lymph node that is serially measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computerized tomography (CT) or magnetic resonance imaging (MRI);
Diagnosis\r\n* Arm 1: subject must have a documented diagnosis of prostate cancer with evidence of lymph node involvement (with a short axis diameter of >= 1.5 cm on a conventional computed tomography [CT] or MRI obtained within 8 weeks of the ferumoxytol imaging procedure)\r\n* Arm 2: subject must have a documented diagnosis of bladder cancer (transitional cell carcinoma) with evidence of lymph node involvement (with a short axis diameter of >= 1.5 cm on a conventional CT or MRI obtained within 8 weeks of the ferumoxytol imaging procedure)\r\n* Arm 3: subject must have a documented diagnosis of kidney cancer (all renal cell cancer types) with evidence of lymph node involvement (with a short axis diameter of >= 1.5 cm on a conventional CT or MRI obtained within 8 weeks of the ferumoxytol imaging procedure)
Measurable disease meeting the following criteria:\r\n* At least 1 lesion of >= 1.0 cm in the longest diameter for a non-lymph node or >= 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI); if there is only one target lesion and it is a non-lymph node, it should have a longest diameter of >= 1.5 cm\r\n* Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion
As measured by conventional high spatial resolution MRI, the minimum diameter of the primary lesion (short axis) should be at least 5 mm
At least 1 lesion of ?1.0 cm in the longest diameter for a non-lymph node or ?1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1 using CT/MRI.
Histologically or cytologically confirmed solid tumors at any stage with at least one lesion (primary, metastatic, or recurrent) ? 1.5 cm in diameter documented by CT. If the lesion is located in a lymph node, the shortest diameter of the lymph node must be ? 1.5 cm as defined by RECIST 1.1. (Note: See Exclusion Criteria #1.)
At least 1 lesion of ?1.0 cm in the longest diameter for a non-lymph node or ?1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) using computed tomography/magnetic resonance imaging (CT/MRI). If there is only 1 target lesion and it is a non-lymph node, it should have a longest diameter of ?1.5 cm.
